These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 35174666)

  • 21. Efficacy of Ubrogepant in the Acute Treatment of Migraine With Mild Pain vs Moderate or Severe Pain.
    Lipton RB; Dodick DW; Goadsby PJ; Burstein R; Adams AM; Lai J; Yu SY; Finnegan M; Kuang AW; Trugman JM
    Neurology; 2022 Oct; 99(17):e1905-e1915. PubMed ID: 35977836
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ubrogepant: An Oral Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist for Abortive Migraine Treatment.
    Nedd M; Garland S; Falk N; Wilk A
    Ann Pharmacother; 2022 Mar; 56(3):346-351. PubMed ID: 34109839
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-world efficacy, tolerability, and safety of ubrogepant.
    Chiang CC; Arca KN; Dunn RB; Girardo ME; Quillen JK; Dodick DW; Starling AJ
    Headache; 2021 Apr; 61(4):620-627. PubMed ID: 33547676
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine.
    Voss T; Lipton RB; Dodick DW; Dupre N; Ge JY; Bachman R; Assaid C; Aurora SK; Michelson D
    Cephalalgia; 2016 Aug; 36(9):887-98. PubMed ID: 27269043
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ubrogepant: Mechanism of action, clinical and translational science.
    Boinpally R; Shebley M; Trugman J
    Clin Transl Sci; 2024 Jan; 17(1):e13675. PubMed ID: 38266060
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ubrogepant Is Safe and Efficacious in Participants Taking Concomitant Preventive Medication for Migraine: A Pooled Analysis of Phase 3 Trials.
    Blumenfeld AM; Knievel K; Manack Adams A; Severt L; Butler M; Lai H; Dodick DW
    Adv Ther; 2022 Jan; 39(1):692-705. PubMed ID: 34874514
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Calcitonin gene-related peptide receptor antagonist ubrogepant for the treatment of acute migraine: A meta-analysis.
    Zhang Z; Shu Y; Diao Y; Du Y; Chen L; Liu Y; Du B
    Medicine (Baltimore); 2021 Feb; 100(8):e24741. PubMed ID: 33663087
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ubrogepant: First Approval.
    Scott LJ
    Drugs; 2020 Feb; 80(3):323-328. PubMed ID: 32020557
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment.
    Kurata A; Yoshida T; Inoue M; Ishizuka T; Nakatsu T; Shimizu T; Kato M; Nishikawa Y; Ishizuka H
    Adv Ther; 2020 Jan; 37(1):253-264. PubMed ID: 31705436
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and efficacy of ubrogepant for the acute treatment of perimenstrual migraine attacks: A post hoc analysis.
    MacGregor EA; Hutchinson S; Lai H; Dabruzzo B; Yu SY; Trugman JM; Ailani J
    Headache; 2023 Sep; 63(8):1135-1144. PubMed ID: 37655536
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reduced hepatic impairment study to evaluate pharmacokinetics and safety of zavegepant and to inform dosing recommendation for hepatic impairment.
    Bhardwaj R; Donohue MK; Madonia J; Morris B; Marbury TC; Matschke KT; Croop R; Bertz R; Liu J
    Clin Transl Sci; 2024 Jul; 17(7):e13813. PubMed ID: 39014555
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Newer Horizon for Treatment of Acute Attack of Migraine: Lasmiditan and Ubrogepant.
    Maitra A; Mukhopadhyay S; Das A; Choudhury S
    Neurol India; 2021; 69(6):1759-1762. PubMed ID: 34979683
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relative efficacy of lasmiditan versus rimegepant and ubrogepant as acute treatments for migraine: network meta-analysis findings.
    Polavieja P; Belger M; Venkata SK; Wilhelm S; Johansson E
    J Headache Pain; 2022 Jul; 23(1):76. PubMed ID: 35790906
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics of vandetanib in subjects with renal or hepatic impairment.
    Weil A; Martin P; Smith R; Oliver S; Langmuir P; Read J; Molz KH
    Clin Pharmacokinet; 2010 Sep; 49(9):607-18. PubMed ID: 20690783
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics, Safety, and Tolerability of Single-Dose Elbasvir in Participants with Hepatic Impairment.
    Marshall WL; Feng HP; Wenning L; Garrett G; Huang X; Liu F; Panebianco D; Caro L; Fandozzi C; Lasseter KC; Preston RA; Marbury T; Butterton JR; Iwamoto M; Yeh WW
    Eur J Drug Metab Pharmacokinet; 2018 Jun; 43(3):321-329. PubMed ID: 29247332
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-World Use of Ubrogepant as Acute Treatment for Migraine with an Anti-Calcitonin Gene-Related Peptide Monoclonal Antibody: Results from COURAGE.
    Lipton RB; Contreras-De Lama J; Serrano D; Engstrom E; Ayasse ND; Poh W; Cadiou F; Manack Adams A
    Neurol Ther; 2024 Feb; 13(1):69-83. PubMed ID: 37910303
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Comprehensive Review of the Mechanism, Efficacy, Safety, and Tolerability of Ubrogepant in the Treatment of Migraine.
    Dighriri IM; Nazel S; Alharthi AM; Altowairqi NA; Albariqi AM; Tohari MA; Alameer AA; Alsaran AK; ALshammari FR; AlMutairi NF; Alsubaie FM; Alharbi TA
    Cureus; 2023 Nov; 15(11):e48160. PubMed ID: 38046695
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of capmatinib in participants with hepatic impairment: A phase 1, open-label, single-dose, parallel-group study.
    Chen X; Cui X; Pognan N; Quinlan M; Kapoor S; Rahmanzadeh G; Giovannini M; Marbury TC
    Br J Clin Pharmacol; 2022 Jan; 88(1):91-102. PubMed ID: 34046915
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of Mild to Severe Hepatic Impairment on the Pharmacokinetics of Sonidegib: A Multicenter, Open-Label, Parallel-Group Study.
    Horsmans Y; Zhou J; Liudmila M; Golor G; Shibolet O; Quinlan M; Emotte C; Boss H; Castro H; Sellami D; Preston RA
    Clin Pharmacokinet; 2018 Mar; 57(3):345-354. PubMed ID: 28577129
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ubrogepant does not induce latent sensitization in a preclinical model of medication overuse headache.
    Navratilova E; Behravesh S; Oyarzo J; Dodick DW; Banerjee P; Porreca F
    Cephalalgia; 2020 Aug; 40(9):892-902. PubMed ID: 32615788
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.